---
title: "HOOKIPA Pharma Inc. (HOOK.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HOOK.US.md"
symbol: "HOOK.US"
name: "HOOKIPA Pharma Inc."
industry: "Biotechnology"
datetime: "2026-04-17T03:14:31.669Z"
locales:
  - [en](https://longbridge.com/en/quote/HOOK.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HOOK.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HOOK.US.md)
---

# HOOKIPA Pharma Inc. (HOOK.US)

## Company Overview

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.hookipapharma.com](https://www.hookipapharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:17.000Z

**Overall: D (0.79)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 316 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -82.54% |  |
| Net Profit YoY | -54.29% |  |
| P/B Ratio | 0.43 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 14660516.28 |  |
| Revenue | 9351000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -105.79% | E |
| Profit Margin | -784.01% | E |
| Gross Margin | -541.67% | E |
| Revenue YoY | -82.54% | E |
| Net Profit YoY | -54.29% | D |
| Total Assets YoY | -58.01% | E |
| Net Assets YoY | -67.39% | E |
| Cash Flow Margin | 71.98% | C |
| OCF YoY | -82.54% | E |
| Turnover | 0.09 | E |
| Gearing Ratio | 44.36% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - HOOKIPA Pharma Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-82.54%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-54.29%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.43",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "14660516.28",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "9351000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-105.79%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-784.01%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-541.67%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-82.54%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-54.29%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-58.01%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-67.39%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "71.98%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-82.54%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.09",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "44.36%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.20 | 105/393 | - | - | - |
| PB | 0.43 | 27/393 | 0.43 | 0.35 | 0.33 |
| PS (TTM) | 1.58 | 41/393 | 1.57 | 1.27 | 1.20 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HOOK.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HOOK.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HOOK.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HOOK.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**